search
Back to results

A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea

Primary Purpose

Primary Dysmenorrhea

Status
Completed
Phase
Phase 4
Locations
Turkey
Study Type
Interventional
Intervention
Piroxicam
Diclofenac Sodium
Sponsored by
Pamukkale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Dysmenorrhea focused on measuring Dysmenorrhea, Piroxicam, Diclofenac Sodium, Emergency department

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • patients were eligible for inclusion if they were aged 18 years or older, 45 years or younger
  • had Primary Dysmenorrhea
  • VAS (visual analog scale) score >5.

Exclusion Criteria:

  • Patients with severe liver, kidney and heart failure
  • After the use of aspirin or other nonsteroidal antiinflammatory drugs, asthma, nasal polyps, angioedema and urticaria to be seen
  • To have active peptic ulcer bleeding or perforation
  • Have a history of upper gastrointestinal disease
  • The presence of Phenylketonuria disease
  • To be Pregnancy and breast-feeding
  • To be Asthma patients
  • Have received analgesics in the last 4 hours
  • Patients of childbearing age who are not using a birth control method.
  • The patient who using digoxin, lithium, furosemide and other diuretics, acetylsalicylic acid and anticoagulant coumadin
  • Physical examination and suspected acute abdomen.

Sites / Locations

  • Pamukkale Universty

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Piroksikam

Diclofenac Sodium

Arm Description

20 mg of piroxicam (feldene ampoule -Pfizer-France) intramuscularly (IM) was given 200 patients,

Second Group: Diclofenac sodium 75mg (Miyadren drug-ampoule -Yavuz Istanbul) intramuscularly (IM) was given 200 patients.

Outcomes

Primary Outcome Measures

Compare decrease of dysmenorrhea VAS (visual analog scale) score between the two groups. - (First group Piroxicam and Second Diclofenac Sodium)

Secondary Outcome Measures

Full Information

First Posted
September 24, 2014
Last Updated
September 27, 2014
Sponsor
Pamukkale University
search

1. Study Identification

Unique Protocol Identification Number
NCT02253446
Brief Title
A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea
Official Title
A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea:A Double-Blind, Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
July 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Pamukkale University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Currently, nonsteroidal antiinflammatory drugs are widely used by emergency physicians in Turkey for the treatment of patients with Primary Dysmenorrhea. The objective of the study is compare intramuscular Diclofenac sodium and piroxicam's pain reduction dysmenorrhea in emergency department (ED) adults. The investigators second aim was to compare recurrent dysmenorrhea pain within 24 hours after discharge.
Detailed Description
this is the randomized double blinded clinical trial to compare the efficacy of these two drugs in this clinical setting. A randomized clinical trial was conducted in the ED of Pamukkale University Medical Faculty Hospital Study personnel (emergency physicians and nurses) were trained before the study. When intramuscular drugs (Piroxicam, Diclofenac sodium) was being recommended, an eligibility checklist was completed by the attending physician. If there were no exclusion criteria, written informed consent was obtained and baseline information, including initial Dysmenorrhea pain severity ratings with VAS were recorded. The need for identification and enrollment of participants by staff with conflicting work pressures resulted in recruitment of a convenience sample of patients. All patients eligible for the study were randomized to one of two groups: First Group: 20 mg of piroxicam (feldene ampoule -Pfizer-France) intramuscularly (IM) was given 200 patients, Second Group: Diclofenac sodium 75mg (Miyadren drug-ampoule -Yavuz Istanbul) intramuscularly (IM) was given 200 patients which determined to be applied as a group. Drug packs prepared in 5 ml syringes were numbered by an independent nurse, who not involved in the study. Drugs were prepared according to the computer-generated random number sequence to assign treatment allocations The allocation list was kept by the emergency nurse. Patients received the piroxicam, diclofenac sodium medication schemes according to their random allocations. After enrollment and recording of baseline information, the next numbered study drug pack was obtained, and administered as a intramuscular. Randomization was achieved by using computer software to generate random numbers. During the intervention, participants were monitored by an oxygen saturation (SpO2) monitor, an automatic sphygmomanometer (blood pressure), and a rhythm monitor (heart rate and rhythms) One researcher blinded to patient allocation observed the whole procedure and recorded the Dysmenorrhea pain scores. Patients in both groups received two types of medication in a similar manner, thus ensuring double blinding. Dysmenorrhea pain scores were recorded at 0, 15, 30, 45 and 60 min on a VAS of 1 to 10 Rescue medication (100 mg of tramadol hydrochloride) was given intramuscular to patients if pain VAS scores ≥ 5 in forty five minutes after study drug administration. All other medications required during the study also were recorded. During the study, pulse rate, systolic blood pressure, diastolic blood pressure, respiration rate and oxygen saturation (SpO2) were recorded at baseline (0 min), 15, 30, and 60 min.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Dysmenorrhea
Keywords
Dysmenorrhea, Piroxicam, Diclofenac Sodium, Emergency department

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
400 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Piroksikam
Arm Type
Experimental
Arm Description
20 mg of piroxicam (feldene ampoule -Pfizer-France) intramuscularly (IM) was given 200 patients,
Arm Title
Diclofenac Sodium
Arm Type
Experimental
Arm Description
Second Group: Diclofenac sodium 75mg (Miyadren drug-ampoule -Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
Intervention Type
Drug
Intervention Name(s)
Piroxicam
Other Intervention Name(s)
Feldene 20 mg/1 mL Solution injectable IM
Intervention Description
20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
Intervention Type
Drug
Intervention Name(s)
Diclofenac Sodium
Other Intervention Name(s)
DICLOMEC (Solution injectable IM), DIKLORON (Solution injectable IM ), MIYADREN (Solution injectable IM ), VOLTAREN (Solution injectable IM )
Intervention Description
Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
Primary Outcome Measure Information:
Title
Compare decrease of dysmenorrhea VAS (visual analog scale) score between the two groups. - (First group Piroxicam and Second Diclofenac Sodium)
Time Frame
Change from Baseline in dysmenorrhea pain VAS scores at 60 minutes.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients were eligible for inclusion if they were aged 18 years or older, 45 years or younger had Primary Dysmenorrhea VAS (visual analog scale) score >5. Exclusion Criteria: Patients with severe liver, kidney and heart failure After the use of aspirin or other nonsteroidal antiinflammatory drugs, asthma, nasal polyps, angioedema and urticaria to be seen To have active peptic ulcer bleeding or perforation Have a history of upper gastrointestinal disease The presence of Phenylketonuria disease To be Pregnancy and breast-feeding To be Asthma patients Have received analgesics in the last 4 hours Patients of childbearing age who are not using a birth control method. The patient who using digoxin, lithium, furosemide and other diuretics, acetylsalicylic acid and anticoagulant coumadin Physical examination and suspected acute abdomen.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mehpare camlibel, MD
Organizational Affiliation
pamukkale universty
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pamukkale Universty
City
Denizli
ZIP/Postal Code
20000
Country
Turkey

12. IPD Sharing Statement

Learn more about this trial

A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea

We'll reach out to this number within 24 hrs